All In Biotech

Free tool

FAERS Monitor: Lastacaft

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022134 or its brand name (Lastacaft, Alcaftadine). Reports on generic versions are filed under their own applications.

Reports

907

Serious

133

15% of reports

Hospitalization

37

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ocular hyperaemia299
  • eye irritation171
  • eye pain103
  • eye pruritus103
  • eye swelling84
  • drug ineffective65
  • hypersensitivity64
  • lacrimation increased57
  • eye discharge47
  • eyelid oedema42
  • erythema of eyelid39
  • conjunctivitis38
  • vision blurred37
  • headache36
  • off label use36

Reports by year received

View as table
YearReports
201160
2012138
201366
2014163
201583
201649
201718
201819
201930
202019
202117
202221
2023104
202467
202537
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
erythema of eyelidSignal39168.2123.66,273
ocular hyperaemiaSignal299147.0133.943,042
eye dischargeSignal47105.479.74,736
eyelid oedemaSignal4284.162.53,355
eye pruritusSignal10371.359.47,059
eye irritationSignal17169.160.411,405
eye swellingSignal8452.542.84,188
conjunctivitisSignal3847.634.91,685
lacrimation increasedSignal5743.834.12,342
eye painSignal10342.435.44,127
hypersensitivitySignal648.06.3388
vision blurredSignal376.34.6159
headache361.31.03
drug ineffective651.10.91
off label use361.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.